The First College of Clinical Medicine, Shandong University of Traditional Chinese Medicine.
The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, China.
Medicine (Baltimore). 2020 Dec 18;99(51):e23747. doi: 10.1097/MD.0000000000023747.
Mycoplasma pneumoniae pneumonia (MPP) is a common respiratory disease in children. Its incidence rate is increasing year by year. The drug resistance rate of macrolide antibiotics and other conventional treatment methods is higher, and there are limitations in clinical application. Traditional Chinese patent medicine (TCPM) is a powerful weapon to treat this disease. At present, there is no comparison of the safety and effectiveness of multiple TCPMs in the treatment of MPP in children. Therefore, we take the method of network meta-analysis to systematically compare the efficacy of various TCPMs in the treatment of this disease.
We will conduct comprehensive searches of Cochrane Library, PubMed, Web of Science, Clinical Trials, China National Knowledge Infrastructure, Chinese Scientific Journals Database, Chinese BioMedical Literature, Wanfang Database, and other electronic databases. The time frame is set from the establishment of the database to October 2020. All randomized controlled trials that meet the inclusion criteria will be included in this study. The 2 researchers will independently screen the literature according to the inclusion criteria, extract the data, and assess the bias risk of the included study. We will evaluate all the obtained data and evidence through Bayesian network meta-analysis, and use Stata 15.0 to process and analyze the data.
Through this study, we will evaluate the efficacy and safety of a variety of TCPMs for the treatment of MPP in children.
The purpose of this study is to provide a strong reference for clinical application of TCPMs in the treatment of MPP in children, and to provide an important basis for clinicians to make correct judgments and put forward accurate treatment plans.
This review does not involve any human or animal experiments and therefore does not require ethical approval.
INPLASY 2020100108.
肺炎支原体肺炎（MPP）是儿童常见的呼吸道疾病，其发病率呈逐年上升趋势。大环内酯类抗生素等常规治疗方法的耐药率较高，临床应用受到限制。中药复方制剂（TCPM）是治疗本病的有力武器。目前，尚无多种 TCPM 治疗儿童 MPP 的安全性和有效性比较。因此，我们采用网络荟萃分析的方法，系统比较各种 TCPM 治疗本病的疗效。
我们将全面检索 Cochrane Library、PubMed、Web of Science、ClinicalTrials、中国知网、中国生物医学文献数据库、中文科技期刊数据库、万方数据库等电子数据库。时间范围设定为数据库建立至 2020 年 10 月。所有符合纳入标准的随机对照试验都将纳入本研究。2 名研究者将根据纳入标准独立筛选文献、提取数据，并评估纳入研究的偏倚风险。我们将通过贝叶斯网络荟萃分析评估所有获得的数据和证据，并使用 Stata 15.0 处理和分析数据。
通过本研究，我们将评估多种 TCPM 治疗儿童 MPP 的疗效和安全性。
本研究旨在为儿童 MPP 治疗中 TCPM 的临床应用提供有力参考，为临床医生做出正确判断、提出准确治疗方案提供重要依据。
本综述不涉及任何人体或动物实验，因此不需要伦理批准。
INPLASY 注册号：INPLASY 2020100108。
